Shanghai, China

Jutong Si

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2022

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Jutong Si: Innovator in Pharmaceutical Development

Introduction

Jutong Si is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer-related mechanisms. With a total of 4 patents to his name, his work is paving the way for innovative treatments.

Latest Patents

One of Jutong Si's latest patents is focused on a histone methyltransferase EZH2 inhibitor. This invention relates to a compound represented by a specific general formula, along with its preparation method and pharmaceutical applications. The compound is designed to treat diseases associated with the histone methyltransferase EZH2, especially cancer. Another notable patent involves a quinoline compound, which also includes a preparation method and medical uses. This novel quinolone compound serves as an inhibitor for various protein kinases and is particularly aimed at the prevention and treatment of cancer.

Career Highlights

Jutong Si is currently employed at Ancureall Pharmaceutical (Shanghai) Co., Ltd. His work at this company has allowed him to focus on innovative pharmaceutical solutions that address critical health issues. His expertise in the field has led to the development of several impactful patents.

Collaborations

Jutong Si collaborates with talented individuals in his field, including Meifeng Jiang and Guan Zhong Wang. These partnerships enhance the research and development efforts at Ancureall Pharmaceutical, fostering an environment of innovation.

Conclusion

Jutong Si's contributions to pharmaceutical inventions highlight his commitment to advancing cancer treatment. His innovative patents and collaborations position him as a key figure in the ongoing battle against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…